<DOC>
	<DOCNO>NCT00745953</DOCNO>
	<brief_summary>Traditionally , obesity consider indirect cause heart disease . Obese individual typically present number traditional Framingham risk factor ( hypertension , dyslipidemia , type 2 diabetes ) , predispose heart attack subsequent heart failure . However , emerge body basic research revisit hypothesis fat direct cardiotoxin . Under healthy condition , triglyceride store fatty tissue ( adipocytes ) amount triglyceride store non-adipocyte tissue ( pancreas , liver , skeletal muscle , heart ) minimal tightly regulate . When regulation disrupt , intracellular triglyceride accumulate excessively organ ( `` steatosis '' ) implicate activate adverse pathway culminate irreversible cell death ( `` lipotoxicity '' ) , lead several well-recognized clinical syndrome . These include non-alcoholic steatohepatitis ( NASH ) , pancreatic beta-cell failure type 2 diabetes , dilate cardiomyopathy . It recently observe angiotensin II receptor blocker ( ARBs ) addition lower blood pressure improve insulin sensitivity decrease risk type 2 diabetes . This study test theory two study group : Valsartan vs. Hydrochlorothiazide . We hypothesize obese human elevate myocardial triglyceride , blockade renin-angiotensin system ( Valsartan group ) reduce myocardial fat improvement insulin sensitivity heart function .</brief_summary>
	<brief_title>Regression Fatty Heart Valsartan Therapy</brief_title>
	<detailed_description>Basic science animal model genetic obesity demonstrate obese , insulin resistant animal fatty heart reduce functional ability . More importantly , insulin sensitize treatment prediabetic rat delay development diabetes improve heart function . A primary aim laboratory translate basic animal research , suggest excessive lipid accumulation myocardium toxic , clinical set use cardiac magnetic resonance imaging/spectroscopy technology . The result research may identify new biomarkers drug target prevent cardiac disease obese human . We use novel vivo magnetic resonance image spectroscopy technique enable quantification triglyceride human myocardium non-invasively , demonstrate obese human like obese animal characterize elevated fat myocardium . We hypothesize obese human elevate myocardial TG , blockade renin-angiotensin system reduce myocardial fat improvement insulin sensitivity heart function . The aim study test obese people impair glucose tolerance ( IGT ) : Aim 1 ) Valsartan treatment reduce myocardial fat improve heart geometry function , Aim 2 ) therapy thiazide diuretic hydrochlorothiazide ( HCTZ ) treatment elevate myocardial fat . We plan test action Valsartan versus HCTZ expect drug cause opposite metabolic effect . The landmark trial ALLHAT ( Antihypertensive Lipid-Lowering Treatment Prevent Heart Attack Trial ) refocus attention thiazide-type diuretic first-line therapy patient hypertension . Despite proven reduction cardiovascular outcome low cost , on-going concern one major side effect thiazides—glucose intolerance—may fuel current U.S. epidemic type 2 diabetes . Despite efficacy low cost thiazide diuretic long know cause insulin resistance , impair glucose tolerance , precipitation overt diabetes .</detailed_description>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Prediabetic individual impair glucose tolerance ( 2 hr postprandial glucose &gt; 140mg/dL ) 3 5 Metabolic Syndrome criterion : 1 . Fasting glucose &gt; 100mg/dL ; 2 . Waist circumference : men &gt; 102cm , woman &gt; 88cm ( confirm abdominal MRI ) ; 3 . HDL : men &lt; 40mg/dL , woman &lt; 50mg/dL ; 4 . Triglycerides &gt; 150mg/dL ; 5 . Blood pressure &gt; 130/80mmHg ; Elevated hepatic triglyceride ( &gt; 5.5 % ) myocardial triglyceride ( &gt; 0.6 % ) Elevated blood triglyceride &gt; 150mg/dL Age &lt; 50 year Type 2 Diabetes mellitus Prior exposure renin system blocker HCTZ BP &gt; 160/100mmHg Claustrophobia Metallic implant body Pregnant planning become pregnant Prior exposure statin medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Metabolic syndrome</keyword>
	<keyword>Lipotoxicity</keyword>
	<keyword>Insulin sensitivity</keyword>
	<keyword>Myocardial triglyceride level</keyword>
	<keyword>Hepatic triglyceride level</keyword>
	<keyword>Magnetic resonance spectroscopy</keyword>
</DOC>